Interim analyses from an ongoing phase I/II trial (NCT04503278) showed significant clinical activity in CAR-T cells targeting CLDN6 when combined with CLDN6-encoding CAR-T cells amplifying RNA vaccine in adult GCT and ovarian carcinoma patients without any evidence of meaningful on-target/off-tumor toxicity [13]. The gene discussed is CLDN6; the disease is granular cell tumor.